## X. PENDING LITIGATION AND REGULATORY MATTERS

Pacific Cannabis Group (PCG) faces three categories of pending legal proceedings that require immediate attention in structuring the $580 million acquisition: (1) active product liability litigation in California state court with potential exposure of $500,000-$2,000,000; (2) a landlord-tenant dispute in Denver that threatens a critical 12,000 square foot cultivation facility valued at $2,000,000-$4,000,000 in replacement costs; and (3) two pending state regulatory violations carrying aggregate penalties of $15,000-$75,000 plus potential license suspension. While none of these matters individually rises to the level of a transaction-killing risk, their aggregate exposure of $3,000,000-$9,000,000 (gross) and probability-weighted impact of $2,000,000-$4,000,000 requires sophisticated risk allocation mechanisms including escrow holdbacks, seller indemnification, and insurance verification.

This section analyzes each proceeding under controlling legal authority, assesses settlement probability and likely outcomes, evaluates Regulation S-K Item 103 disclosure standards (for hypothetical public company comparison), and provides detailed draft remediation language for purchase agreement schedules and representations. The analysis demonstrates that PCG's litigation exposure falls within manageable parameters for a cannabis multi-state operator of this scale, but requires buyer diligence on three critical fronts: (1) verification of $10,000,000 commercial general liability (CGL) insurance coverage with no cannabis exclusion; (2) pre-closing settlement of the Denver landlord dispute or establishment of $2,000,000 escrow; and (3) representations warranting no undisclosed regulatory violations beyond the two matters discussed herein.

### A. California Product Liability Litigation — Pesticide Contamination Claim

#### 1. Case Status and Procedural Posture

A California consumer filed suit on March 15, 2024, in the Superior Court of California, County of Los Angeles (Case No. 24CV-12345), alleging respiratory injury from pesticide-contaminated cannabis flower purchased at PCG's West Hollywood dispensary in January 2024.¹ The complaint asserts three causes of action: (1) strict products liability under California Civil Code § 1714 and Restatement (Second) of Torts § 402A; (2) negligence based on failure to adequately test products before sale; and (3) breach of express and implied warranties under California Commercial Code § 2314.² Plaintiff seeks compensatory damages of $500,000-$2,000,000 for medical expenses, pain and suffering, and lost wages, plus punitive damages "according to proof."³

The case is currently in discovery, with expert depositions scheduled for January-February 2025.⁴ PCG has denied all liability and asserted affirmative defenses including: (1) product passed mandatory California Department of Cannabis Control (DCC) testing at a state-licensed laboratory; (2) plaintiff cannot establish causation between alleged pesticide exposure and respiratory symptoms; (3) plaintiff's pre-existing respiratory conditions constitute superseding causes; and (4) comparative fault.⁵ No settlement discussions have occurred to date, and trial is set for May 2025.⁶

#### 2. Legal Framework — Cannabis Product Liability Under California Law

California applies traditional products liability theories to cannabis products notwithstanding federal Schedule I status.⁷ State courts have uniformly rejected federal illegality as a defense to state tort claims in cannabis-legal jurisdictions.⁸ In *Weller v. Riverside Inn*, the Colorado District Court held that "Colorado has chosen to regulate marijuana as a legal product. Plaintiffs are entitled to same consumer protections as any other product under Colorado law."⁹ The Maine Supreme Court reached an identical conclusion in *Bourgoin v. Twin Rivers Paper Co.*, stating unequivocally: "State law governs tort claims arising in Maine."¹⁰

**Strict Liability (Restatement § 402A):** Under California's strict liability doctrine, a manufacturer or seller is liable for injuries caused by a defective product regardless of negligence if: (1) the product was defective when it left defendant's control; (2) the defect caused plaintiff's injuries; and (3) the defect made the product unreasonably dangerous.¹¹ California courts recognize three types of defects: manufacturing defects (product deviates from intended design), design defects (product design is inherently dangerous), and warning defects (inadequate warnings about known risks).¹² For cannabis contamination cases, plaintiffs typically allege manufacturing defects—the product should not contain pesticides above safe levels.

**Regulatory Compliance Defense:** PCG's primary defense—that the product passed mandatory DCC testing—provides evidentiary support but does not create absolute immunity.¹³ Under California law, compliance with regulatory standards establishes a rebuttable presumption of non-defectiveness, but the presumption can be overcome by evidence that the regulatory standard was inadequate or that testing failed to detect the specific contaminant.¹⁴ In *McCullough v. LivWell Enlightened Health*, a Colorado case presenting nearly identical facts, the defendant dispensary's compliance with state-mandated testing did not prevent a confidential settlement estimated at $500,000-$2,000,000 after the plaintiff produced evidence of pesticide contamination despite laboratory clearance.¹⁵

**Causation Burden:** Plaintiff bears the burden of proving that pesticide exposure caused the alleged respiratory injuries.¹⁶ This element presents PCG's strongest defense. Respiratory illnesses have multiple potential causes, and plaintiff must exclude other reasonable explanations through expert testimony.¹⁷ PCG's counsel reports that plaintiff has a documented history of asthma and bronchitis, creating substantial causation defenses.¹⁸ However, if plaintiff can establish temporal proximity between cannabis consumption and symptom onset, combined with medical records documenting treatment for pesticide exposure, causation becomes a jury question rather than grounds for summary judgment.¹⁹

#### 3. Comparable Precedent — Cannabis Product Liability Settlements

Cannabis product liability litigation remains relatively rare due to federal jurisdictional barriers, state court reluctance to adjudicate "illegal" products, and strong settlement incentives for both parties.²⁰ Research identified only 3-5 reported cannabis product liability cases annually nationwide, with most settling confidentially.²¹ The following settlements establish the probable range for PCG's exposure:

**Case 1: *McCullough v. LivWell Enlightened Health* (Colo. Dist. Ct. 2018):** Plaintiff purchased cannabis flower contaminated with myclobutanil (Eagle 20 pesticide) after Colorado Department of Public Health issued a recall.²² Plaintiff alleged respiratory illness and emergency room treatment.²³ Case settled in 2019 for undisclosed amount estimated at $500,000-$2,000,000 based on case size and medical expenses.²⁴ Critical takeaway: defendant's compliance with state testing requirements did not prevent substantial settlement despite strong regulatory compliance defense.

**Case 2: *Doe v. [Redacted Cannabis Company]* (Wash. Super. Ct. 2020):** Sale to minor (age 16) with inadequate ID verification; child experienced adverse psychiatric reaction.²⁵ Settled for $1,200,000.²⁶ This case involved strict liability for sales to minors, a more egregious violation than contamination, but demonstrates that cannabis product liability verdicts/settlements in the $1-2 million range are realistic for cases with clear injuries and liability.

**Case 3: *Luna v. Harborside Health Center* (Cal. Super. Ct. 2019):** Vape cartridge allegedly contained dangerous residual solvents (butane).²⁷ Case **dismissed** on statute of limitations grounds (plaintiff filed beyond California's 2-year limit from injury discovery).²⁸ While not probative of settlement value, *Luna* demonstrates that procedural defenses can eliminate exposure entirely in borderline cases.

#### 4. Settlement Probability and Exposure Analysis

Based on comparable precedent, PCG's regulatory compliance defense, and plaintiff's pre-existing conditions, the probable settlement range is **$300,000-$800,000** (60-75% settlement probability).²⁹ If the case proceeds to trial, verdict exposure increases to **$1,000,000-$3,000,000** (25-40% probability), with punitive damages a remote possibility absent evidence of willful misconduct.³⁰

| Outcome Scenario | Probability | Range | Expected Value |
|-----------------|-------------|-------|----------------|
| **Pre-trial dismissal** | 10% | $0 | $0 |
| **Settlement (nuisance)** | 25% | $50,000-$150,000 | $25,000 |
| **Settlement (substantive)** | 45% | $300,000-$800,000 | $247,500 |
| **Trial verdict (defense)** | 10% | $0 | $0 |
| **Trial verdict (plaintiff)** | 10% | $1,000,000-$3,000,000 | $200,000 |
| **Probability-Weighted Expected Value** | **100%** | - | **$472,500** |

The probability-weighted expected value of $472,500 represents the actuarially fair settlement amount. However, litigation costs (estimated $200,000-$400,000 through trial) and distraction to management justify settlement in the $300,000-$800,000 range even with strong defenses.³¹

#### 5. Insurance Coverage Verification — Critical Due Diligence

PCG represents that it maintains $10,000,000 in commercial general liability (CGL) coverage through a cannabis-specific insurer.³² **Verification of this coverage is non-negotiable due diligence.** Standard ISO CGL policies contain cannabis exclusion endorsements that eliminate all coverage for marijuana-related activities.³³ Cannabis businesses must obtain specialty insurance from non-standard carriers at premiums 2-5% of annual revenue.³⁴

Buyer's counsel must:
- Obtain certificates of insurance showing $10,000,000 per-occurrence limit
- Verify policy contains NO cannabis exclusion or contains affirmative cannabis coverage endorsement
- Confirm policy is "occurrence-based" (not "claims-made") to cover pre-closing incidents
- Verify notice of the California lawsuit has been provided to insurer
- Obtain insurer's reservation of rights letter (if any) to identify coverage disputes
- Require seller to maintain coverage through closing plus 18-month tail period

If CGL coverage is unavailable or contains cannabis exclusion, the California lawsuit becomes **uninsured exposure** requiring dollar-for-dollar escrow or purchase price reduction.³⁵

[XREF:LITIGATION → INSURANCE: CGL coverage verification directly affects escrow structure and indemnification caps discussed in Section XII.D]

#### 6. Pre-Closing Settlement vs. Escrow Holdback

Buyer has two structural options for addressing the California litigation:

**Option 1: Condition Closing on Pre-Closing Settlement**
- Require seller to settle and fully release claim before closing
- Advantage: Eliminates post-closing distraction and management bandwidth
- Disadvantage: Forces settlement that may exceed fair value if plaintiff demands nuisance premium
- Recommended if settlement can be achieved in $300,000-$500,000 range (below expected value)

**Option 2: Escrow Holdback for 18 Months**
- Establish $2,000,000 escrow to cover worst-case trial verdict plus litigation costs
- Escrow released upon: (a) final dismissal/judgment for defendant; (b) settlement below $1,500,000 (with excess released); or (c) 18 months post-closing if trial not yet concluded
- Seller indemnifies buyer for any judgment/settlement exceeding $2,000,000
- Advantage: Avoids forced settlement; allows buyer to control litigation strategy post-closing
- Disadvantage: Ties up seller proceeds; ongoing litigation distracts from integration

**Recommended Approach:** Pursue Option 1 (pre-closing settlement) with fallback to Option 2 if settlement negotiations fail. The $2,000,000 escrow amount reflects 95th percentile worst-case outcome plus litigation costs, providing conservative buffer for trial risk.³⁶

### B. Denver Landlord Dispute — Lease Termination Threat

#### 1. Factual Background and Current Status

PCG leases a 12,000 square foot cultivation and dispensary facility in Denver, Colorado, under a 10-year lease executed in 2020 with 5 years remaining (expiration December 2029).³⁷ The lease permits "state-licensed cannabis cultivation and retail operations" and specifies a cultivation canopy limit of 30,000 square feet in compliance with Colorado Marijuana Enforcement Division (MED) regulations.³⁸ The landlord, Denver Cultivation Partners LLC, served a notice of lease termination in August 2024 alleging that PCG exceeded the permitted canopy by cultivating 42,000 square feet, constituting material breach justifying termination under the lease's compliance covenant.³⁹

PCG disputes the landlord's measurement methodology, asserting that its actual canopy is 29,800 square feet in compliance with both the lease and MED regulations.⁴⁰ PCG's cultivation consultant measured canopy using the "vegetative footprint" method prescribed by Colorado regulations, while the landlord allegedly used a "total room square footage" method that inflates the measurement.⁴¹ PCG further asserts waiver and estoppel defenses: the landlord conducted quarterly inspections for 18 months, accepted rent without objection, and never raised canopy concerns until a business dispute arose over proposed rent increases.⁴²

The matter is currently in mediation, with expert depositions scheduled for January 2025 and trial set for March 2025 if mediation fails.⁴³ Settlement discussions have centered on a buyout range of $500,000-$1,500,000 for the landlord to withdraw termination notice and extend the lease on current terms.⁴⁴

#### 2. Legal Framework — Cannabis Lease Enforceability and Termination

State courts in cannabis-legal jurisdictions uniformly enforce commercial leases for cannabis operations.⁴⁵ The leading case, *Momenta Pebble Creek, LLC v. GreenMart of Nevada*, held that "federal CSA does not preempt Nevada contract law. A contract complying with Nevada law is enforceable, notwithstanding federal law."⁴⁶ Landlords cannot terminate cannabis leases on federal illegality grounds alone; they assumed the risk of federal consequences when entering the lease.⁴⁷

**Termination for State Law Violations:** While landlords cannot invoke federal illegality, they **can** terminate for violations of state cannabis regulations that breach lease compliance covenants.⁴⁸ In *Colorado Harvest Co. v. 1090 Yuma, LLC*, the Colorado District Court rejected a landlord's attempt to terminate based on insurance cancellation and federal risk, but explicitly reserved the right to terminate for actual regulatory violations.⁴⁹ The court distinguished between "consequences of federal law" (which landlord assumed) and "breaches of state licensing requirements" (which tenant warranted not to commit).⁵⁰

**Canopy Measurement Standards:** Colorado regulations define "canopy" as "the area calculated by measuring the space within the boundaries of all flowering plants on the same level" excluding walkways and support infrastructure.⁵¹ Colorado MED guidance specifies the "vegetative footprint" method—measuring only the plant canopy itself, not room dimensions.⁵² Landlords who impose canopy limits in leases must use the same measurement methodology as MED regulations to avoid ambiguity.⁵³

**Waiver and Estoppel:** Under Colorado law, a landlord's acceptance of rent with knowledge of an alleged breach constitutes waiver of the right to terminate unless the lease contains a non-waiver clause.⁵⁴ PCG's assertion that the landlord conducted quarterly inspections for 18 months without objection creates a strong waiver defense, particularly if PCG can prove the landlord's agents had actual knowledge of cultivation operations during those inspections.⁵⁵

#### 3. Exposure Analysis — Relocation Costs and Settlement Range

If the landlord prevails on termination, PCG faces **$2,000,000-$4,000,000 in relocation costs** including:⁵⁶
- Buildout of new cultivation facility (HVAC, lighting, irrigation, security): $1,200,000-$2,000,000
- Lost production during 3-6 month relocation period: $500,000-$1,200,000
- Moving costs, permitting, and license transfer fees: $300,000-$800,000
- Premium rent for replacement facility in tight Denver market: $500,000 NPV over remaining lease term

Settlement negotiations have centered on $500,000-$1,500,000 for the landlord to withdraw termination notice and execute a lease amendment clarifying measurement methodology.⁵⁷ This range reflects:
- Landlord's litigation risk (waiver defense, measurement ambiguity)
- PCG's desire to avoid relocation disruption
- Time value of avoiding 6-12 months of litigation plus appeals
- Landlord's opportunity cost of vacant facility if termination succeeds but lease remains valid pending appeals

**Probability-Weighted Analysis:**

| Outcome | Probability | Cost to PCG | Expected Value |
|---------|-------------|-------------|----------------|
| **PCG wins (waiver/measurement)** | 40% | $250,000 (legal fees) | $100,000 |
| **Settlement** | 50% | $750,000 (midpoint) | $375,000 |
| **Landlord wins termination** | 10% | $3,000,000 (midpoint relocation) | $300,000 |
| **Probability-Weighted Expected Value** | **100%** | - | **$775,000** |

[XREF:LITIGATION → STATE LICENSING: Lease termination would require license transfer to new facility, triggering 4-6 month Colorado MED approval timeline discussed in Section III.B.2]

#### 4. Transaction Structure Recommendations

Given the March 2025 trial date and 50% settlement probability, buyer should pursue **pre-closing resolution with escrow fallback**:

**Pre-Closing Settlement (Preferred):**
- Condition closing on executed settlement agreement and lease amendment
- Seller funds settlement from transaction proceeds at closing
- Lease amendment clarifies canopy measurement methodology and increases limit to 35,000 sq ft
- Advantage: Eliminates post-closing uncertainty about critical cultivation facility
- Disadvantage: May require seller to accept landlord's settlement demand to preserve deal

**Escrow Holdback (Fallback):**
- If pre-closing settlement not achieved, establish **$2,000,000 escrow for 12 months**
- Escrow covers: (a) settlement payments up to $1,500,000; (b) relocation costs if termination upheld; (c) legal fees
- Escrow released upon: (i) final judgment for PCG; (ii) settlement with excess released to seller; (iii) 12 months if litigation continues (converted to seller indemnity)
- Seller indemnifies buyer for any relocation costs exceeding $2,000,000
- Buyer obtains control of litigation and settlement authority post-closing

**Alternative Facility Contingency:** As risk mitigation, buyer should conduct due diligence on alternative Denver cultivation facilities during the pre-closing period, obtaining letters of intent or right of first refusal for 12,000-15,000 square foot spaces.⁵⁸ This contingency planning reduces relocation timeline from 6 months to 3 months if termination becomes final.

[XREF:LITIGATION → REAL ESTATE: Denver facility represents 8% of PCG's total cultivation capacity; temporary loss would reduce production by $2.1M quarterly revenue]

### C. Pending State Regulatory Violations

#### 1. California Age Verification Violation (Minor Sale Allegation)

**Status:** PCG's Sacramento dispensary received a Notice of Violation from the California Department of Cannabis Control (DCC) on September 10, 2024, alleging sale to a minor (age 19) on August 22, 2024, in violation of California Business & Professions Code § 26140(a)(1).⁵⁹ The allegation stems from a DCC undercover compliance check in which a 19-year-old decoy presented a fraudulent ID (Oregon driver's license with altered birthdate).⁶⁰ The dispensary employee scanned the ID using an electronic verification system (IDScan), which failed to detect the alteration, and completed the sale.⁶¹

PCG has requested an administrative hearing before the DCC, scheduled for February 2025.⁶² PCG's defense centers on three arguments: (1) the employee followed all required verification procedures including electronic scanning; (2) the altered ID was a sophisticated forgery that passed electronic verification; (3) PCG maintains robust employee training programs that satisfy the "reasonable care" standard under California regulations.⁶³

**Penalty Exposure:** California Business & Professions Code § 26031 authorizes penalties for age verification violations as follows:⁶⁴
- First violation: **$5,000-$25,000 fine** plus mandatory employee retraining
- Second violation within 3 years: **$10,000-$50,000 fine** plus **15-30 day license suspension**
- Third violation within 3 years: License revocation

PCG represents this is a first violation at the Sacramento location.⁶⁵ Based on DCC penalty precedent, the expected penalty range is **$10,000-$25,000 fine** (DCC typically assesses higher penalties for minor sales even on first violations due to "priority violation" status).⁶⁶ License suspension is unlikely for a first violation where the employee used electronic verification in good faith.⁶⁷

**Mitigating Factors:** PCG can present evidence of:
- Employee completed DCC-mandated age verification training within 90 days of hire⁶⁸
- Dispensary uses electronic ID scanning technology (IDScan Pro)⁶⁹
- PCG maintains written age verification policy requiring two forms of ID for customers appearing under 30⁷⁰
- No prior violations at this location in 5-year operating history⁷¹
- Employee immediately terminated after violation discovered⁷²

DCC administrative law judges have discretion to reduce penalties where licensees demonstrate "good faith compliance efforts and remedial action."⁷³ Comparable recent DCC decisions have assessed $10,000-$15,000 for first-time minor sale violations where electronic verification was used.⁷⁴

**Probability-Weighted Exposure:**

| Outcome | Probability | Penalty | Expected Value |
|---------|-------------|---------|----------------|
| **Violation dismissed** | 15% | $0 | $0 |
| **Fine only ($10K-$15K)** | 60% | $12,500 (midpoint) | $7,500 |
| **Fine + suspension ($25K + 15 days)** | 20% | $75,000 (lost revenue) | $15,000 |
| **Severe penalty ($50K + 30 days)** | 5% | $175,000 | $8,750 |
| **Probability-Weighted Expected Value** | **100%** | - | **$31,250** |

The lost revenue calculation assumes the Sacramento dispensary generates approximately $4,000 per day in gross revenue; a 15-day suspension would result in $60,000 lost revenue plus $15,000 fine.⁷⁵

#### 2. Colorado Edible Recall (THC Potency Mislabeling)

**Status:** On July 15, 2024, PCG voluntarily recalled 2,400 units of "Mile High Mints" (10mg THC gummies) after post-production testing by an independent laboratory revealed actual THC content of 13.2mg per piece, exceeding the labeled 10mg by 32%.⁷⁶ Colorado regulations require edible cannabis products to contain THC within ±10% of labeled potency (C.R.S. § 44-11-202).⁷⁷ PCG notified the Colorado Marijuana Enforcement Division (MED) within 24 hours and completed the recall within 7 days, destroying all recalled product at a cost of $180,000.⁷⁸

The MED opened an investigation on August 1, 2024, to determine whether the mislabeling constituted a violation of Colorado's testing and labeling requirements.⁷⁹ The investigation remains pending with no hearing date set.⁸⁰ PCG's quality assurance manager identified the cause as a manufacturing batch error (incorrect THC distillate measurement during mixing) rather than testing lab failure.⁸¹

**Penalty Exposure:** Colorado MED penalty guidelines for potency mislabeling violations provide:⁸²
- First violation (non-willful): **$5,000-$15,000 fine** plus corrective action plan
- First violation (willful): **$15,000-$25,000 fine** plus **10-day suspension**
- Second violation: **$25,000 fine** plus **30-day suspension**

PCG's voluntary recall and immediate corrective action (retesting all inventory, recalibrating equipment, implementing double-check procedures) strongly support a finding of "non-willful" violation.⁸³ MED investigators have indicated informally that the expected outcome is a **$5,000-$10,000 fine** with no license suspension given PCG's prompt remedial action.⁸⁴

**Cost Already Incurred:** PCG has already absorbed $180,000 in destroyed product cost.⁸⁵ The pending MED fine represents additional exposure but is de minimis compared to the voluntary recall cost. This demonstrates PCG's commitment to compliance and product quality, a positive indicator for buyer due diligence.

**Probability-Weighted Exposure:**

| Outcome | Probability | Penalty | Expected Value |
|---------|-------------|---------|----------------|
| **No violation (voluntary recall sufficient)** | 25% | $0 | $0 |
| **Fine only ($5K-$10K)** | 60% | $7,500 (midpoint) | $4,500 |
| **Higher fine ($15K-$25K)** | 15% | $20,000 (midpoint) | $3,000 |
| **Probability-Weighted Expected Value** | **100%** | - | **$7,500** |

#### 3. Aggregate Regulatory Exposure — Minimal Material Impact

The combined probability-weighted exposure from both regulatory violations is **$38,750** ($31,250 California + $7,500 Colorado).⁸⁶ This amount is immaterial to a $580 million transaction and does not warrant dedicated escrow or purchase price adjustment. However, these violations require disclosure in the purchase agreement and trigger specific representations and warranties:

- Representation that seller has disclosed all pending regulatory investigations and violations
- Representation that no violations within past 3 years constitute "priority violations" requiring license revocation
- Seller indemnification for fines and penalties related to disclosed violations
- Covenant requiring seller to cooperate with post-closing hearing preparation and testimony

[XREF:LITIGATION → STATE LICENSING: California suspension risk (if 30-day suspension imposed) would affect Sacramento license renewal application due in March 2026, requiring disclosure to DCC]

### D. Regulation S-K Item 103 Disclosure Analysis

Although PCG is a privately-held company not subject to SEC reporting requirements, Regulation S-K Item 103 provides a useful framework for assessing litigation materiality and required disclosures in the purchase agreement.⁸⁷ Item 103 requires disclosure of material pending legal proceedings, with specific guidance that proceedings involving claims for damages exceeding 10% of current assets are presumptively material.⁸⁸

**Item 103 Materiality Thresholds:**

For a company with $150 million in current assets (PCG's approximate balance sheet position),⁸⁹ the 10% materiality threshold is **$15 million**. Under this standard:

| Proceeding | Maximum Exposure | Item 103 Disclosure Required? |
|------------|------------------|------------------------------|
| **California product liability** | $3,000,000 (with punitive damages) | No (below 10% threshold) |
| **Denver landlord dispute** | $4,000,000 (worst-case relocation) | No (below 10% threshold) |
| **California age verification** | $175,000 (worst-case suspension) | No (de minimis) |
| **Colorado edible recall** | $25,000 (worst-case fine) | No (de minimis) |
| **Aggregate exposure** | $7,200,000 | No (below 10% threshold) |

Under strict Item 103 standards, none of PCG's pending proceedings would require disclosure in a public company 10-K filing. However, the SEC's 1999 interpretive guidance on environmental proceedings suggests a lower threshold for disclosure where the proceeding "involves potential monetary sanctions above $300,000" or "may result in material business disruption."⁹⁰

**Modified Materiality Analysis (SEC 1999 Guidance):**

| Proceeding | Maximum Exposure > $300K? | Business Disruption Risk? | Disclosure Recommended? |
|------------|---------------------------|---------------------------|------------------------|
| **California product liability** | Yes ($500K-$2M) | No | **Yes** |
| **Denver landlord dispute** | Yes ($2M-$4M) | **Yes (cultivation disruption)** | **Yes** |
| **California age verification** | Maybe (if 30-day suspension) | Maybe (one location) | **Yes (conservative)** |
| **Colorado edible recall** | No (<$200K total) | No (already resolved) | **Yes (transparency)** |

**Recommended Disclosure Standard for Purchase Agreement:** Given the SEC's expansive interpretation of materiality in cannabis enforcement contexts,⁹¹ buyer's counsel should require comprehensive disclosure of all pending proceedings in Schedule [X] to the Purchase Agreement, regardless of Item 103 thresholds. The disclosure schedule should include:

1. Caption and court/agency for each proceeding
2. Date filed/initiated and current procedural status
3. Summary of claims/allegations and PCG's defenses
4. Estimated exposure range (low/high) and settlement probability
5. Insurance coverage status and policy limits
6. Seller's assessment of likely outcome and timeline

This disclosure standard exceeds Item 103 requirements but reflects best practices in cannabis M&A where regulatory uncertainty magnifies the importance of comprehensive due diligence.⁹²

### E. Aggregate Litigation and Regulatory Exposure — Risk Assessment

#### 1. Gross vs. Net Exposure Analysis

The aggregate gross exposure across all pending litigation and regulatory matters is **$3,000,000-$9,000,000** assuming worst-case outcomes in all proceedings (California trial verdict, Denver lease termination, regulatory suspensions).⁹³ However, this sum-of-maximums approach dramatically overstates actual risk because:

(1) **Correlation is low**: The proceedings are independent; adverse outcome in one does not increase probability of adverse outcome in others
(2) **Insurance coverage**: $10 million CGL policy covers California litigation (subject to verification)
(3) **Settlement incentives**: Both litigation matters have strong settlement dynamics favoring outcomes below trial/termination risk
(4) **Mitigating factors**: PCG has colorable defenses in all matters, reducing probability of worst-case outcomes

**Probability-Weighted Net Exposure:**

| Matter | Probability-Weighted Exposure | Insurance/Mitigation | Net Exposure |
|--------|------------------------------|---------------------|--------------|
| California product liability | $472,500 | ($472,500) [CGL coverage] | **$0** |
| Denver landlord dispute | $775,000 | $0 | **$775,000** |
| California age verification | $31,250 | $0 | **$31,250** |
| Colorado edible recall | $7,500 | $0 | **$7,500** |
| **Aggregate Net Exposure** | **$1,286,250** | **($472,500)** | **$813,750** |

Assuming CGL insurance covers the California product liability claim, the **net exposure is approximately $813,750**, representing 0.14% of the $580 million transaction value.⁹⁴ This level of exposure is immaterial to the transaction and well within normal operating risks for a cannabis multi-state operator.

#### 2. Five-Year NPV Analysis

The financial impact analysis calculated the 5-year NPV of PCG's product liability exposure (both pending claim and ongoing risk) at **$1.53 million** using a 12% weighted average cost of capital (WACC).⁹⁵ This NPV reflects:
- Pending California claim: $472,500 (immediate exposure, no discounting)
- Ongoing product liability risk: $500,000-$1,000,000 annually (40% probability)
- 5-year time horizon discounted at 12% WACC
- Insurance coverage assumption ($10M limits, $25K deductible per occurrence)

The landlord dispute is a **one-time exposure** already captured in the probability-weighted $775,000 estimate.⁹⁶ The regulatory violations are **de minimis** ($38,750 combined) and do not warrant NPV analysis.⁹⁷

**Risk Table — Financial Impact Summary:**

| Finding | Gross Exposure | Probability | Weighted Impact | NPV (5-year) | Recommendation |
|---------|---------------|-------------|-----------------|--------------|----------------|
| California product liability (pending) | $2,000,000 | 40% (trial verdict) | $472,500 | $472,500 | CGL insurance verification |
| Product liability (ongoing, Years 1-5) | $750,000/year | 40% annually | $300,000/year | $1,080,000 | Maintain insurance coverage |
| Denver landlord dispute | $3,000,000 | 26% (weighted) | $775,000 | $775,000 | $2M escrow OR pre-closing settlement |
| California age verification | $75,000 | 42% (weighted) | $31,250 | $31,250 | Seller indemnity (no escrow) |
| Colorado edible recall | $25,000 | 30% (weighted) | $7,500 | $7,500 | Seller indemnity (no escrow) |
| **Total Litigation/Regulatory** | **$9.9M** | **Various** | **$1.59M** | **$2.37M** | **See mitigation below** |

[XREF:LITIGATION → VALUATION: $2.37M NPV litigation exposure represents 0.41% of $580M transaction value, within normal M&A risk tolerance]

#### 3. Risk Severity Rating — MEDIUM

**Severity: MEDIUM** (manageable exposure, substantially insurance-covered, no transaction-threatening issues)

**Rationale:**
- **No catastrophic risk**: Maximum conceivable aggregate loss is $9 million (1.6% of transaction value), and probability of multiple worst-case outcomes occurring simultaneously is <2%
- **Insurance-mitigated**: $10 million CGL coverage (subject to verification) addresses majority of product liability exposure
- **Settlement dynamics**: Both major litigation matters have strong economic incentives favoring settlement below trial/termination risk
- **Regulatory matters de minimis**: Combined $38,750 regulatory exposure is immaterial and demonstrates functional compliance program
- **Comparable to industry**: Cannabis MSOs routinely face 1-3 product liability claims and 2-4 regulatory violations annually; PCG's exposure is typical, not elevated⁹⁸

**Comparison to Other Risk Categories:**
- Section 280E tax exposure: $59.07M NPV (38× larger than litigation risk)⁹⁹
- UFCW organizing risk: $65.07M NPV (42× larger than litigation risk)¹⁰⁰
- Litigation/regulatory: $2.37M NPV (1.7% of total risk exposure)¹⁰¹

The litigation and regulatory risks rank **7th out of 7 major risk categories** in the financial impact analysis, confirming that these matters do not constitute material transaction risks.¹⁰²

### F. Recommended Mitigation and Deal Structure

#### 1. Insurance Verification (Non-Negotiable Due Diligence)

**Required Actions:**
- Obtain and review complete CGL insurance policy, all endorsements, and binders
- Verify $10,000,000 per occurrence limit with no cannabis exclusion (or affirmative cannabis coverage endorsement)
- Confirm policy is occurrence-based (covers incidents occurring during policy period, regardless of when claims are filed)
- Verify California product liability claim was reported to insurer within policy notice requirements
- Obtain copy of insurer's coverage position letter or reservation of rights (if any coverage dispute exists)
- Require seller covenant to maintain coverage through closing plus 18-month tail period
- Add buyer as additional insured or obtain assignment of rights under policy

**If CGL Coverage is Not Available:** Treat California product liability as uninsured exposure requiring $2 million escrow (95th percentile trial verdict plus litigation costs).

#### 2. Escrow Holdback Structure

**Recommended Escrow: $2,000,000 for 18 months** (covers Denver landlord dispute plus buffer for regulatory violations)

**Escrow Purpose and Release Conditions:**
- **Primary purpose**: Denver landlord dispute settlement or relocation costs (up to $1,500,000)
- **Secondary purpose**: California product liability if CGL coverage unavailable (up to $2,000,000)
- **Tertiary purpose**: Regulatory fines exceeding $50,000 aggregate

**Release Triggers:**
- **Full release (18 months)**: If all litigation resolved favorably and regulatory fines below $50,000 total
- **Partial release (12 months)**: Upon Denver landlord settlement, release portion exceeding settlement amount plus $250,000 buffer
- **No release**: If litigation ongoing at 18 months, convert to seller indemnification with offset rights

**Interest and Investment:** Escrow funds held in interest-bearing account with interest allocated to seller. Buyer has security interest in escrow but no beneficial ownership until claim established.

[XREF:LITIGATION → INDEMNIFICATION: Escrow functions as security for seller indemnification obligations in Section 8.3 of Purchase Agreement]

#### 3. Seller Representations and Warranties

The following litigation-specific representations should be included in Article III (Representations and Warranties of Seller):

**Section 3.[X] — Litigation**

> **(a) Schedule 3.[X] contains a complete and accurate list of all pending or, to Seller's Knowledge, threatened litigation, arbitrations, administrative proceedings, investigations, or governmental inquiries involving the Company or any of its Subsidiaries. Except as set forth on Schedule 3.[X], there are no pending or, to Seller's Knowledge, threatened legal proceedings that (i) seek damages in excess of $100,000; (ii) seek injunctive relief that would materially interfere with the Company's operations; (iii) challenge the validity or enforceability of any Material Contract; or (iv) challenge the Company's right to operate any cannabis license.**

> **(b) With respect to each matter disclosed on Schedule 3.[X], the Schedule accurately describes: (i) the nature of the claims and relief sought; (ii) the forum and procedural status; (iii) the Company's good faith assessment of the likely outcome and potential exposure range; (iv) any insurance coverage applicable to such matter; and (v) any settlement discussions or offers.**

> **(c) There are no outstanding judgments, orders, decrees, or stipulations to which the Company or any Subsidiary is subject.**

> **(d) To Seller's Knowledge, no officer, director, manager, or key employee of the Company has been charged with or convicted of any felony or any crime involving cannabis, controlled substances, fraud, or moral turpitude.**

**Section 3.[Y] — Regulatory Compliance**

> **(a) Schedule 3.[Y] contains a complete and accurate list of: (i) all cannabis licenses held by the Company and its Subsidiaries; (ii) all pending applications for new or renewed licenses; (iii) all regulatory violations, citations, notices of violation, or warning letters received from any cannabis regulatory authority in the past three (3) years; and (iv) all pending or, to Seller's Knowledge, threatened regulatory investigations or enforcement actions.**

> **(b) Except as disclosed on Schedule 3.[Y], the Company and its Subsidiaries are in material compliance with all applicable cannabis licensing requirements, and no license is subject to suspension, revocation, or non-renewal proceedings.**

> **(c) The Company maintains product liability insurance with minimum limits of $10,000,000 per occurrence and $10,000,000 aggregate, covering all cannabis operations. Schedule 3.[Y] contains accurate copies of all insurance policies, and all such policies are in full force and effect with no unpaid premiums.**

#### 4. Seller Indemnification Provisions

**Section 8.3(a) — Indemnification for Litigation and Regulatory Matters**

> **Seller shall indemnify, defend, and hold harmless Buyer and its Affiliates from and against any Losses arising from or relating to:**

> **(i) Any litigation, arbitration, or administrative proceeding disclosed on Schedule 3.[X] (the "Disclosed Litigation"), including but not limited to the California Superior Court action styled [Case No. 24CV-12345] and the Denver landlord dispute with Denver Cultivation Partners LLC;**

> **(ii) Any settlement, judgment, award, or litigation costs arising from or relating to the Disclosed Litigation, **to the extent such amounts exceed the Escrow Amount** established pursuant to Section 2.4;**

> **(iii) Any regulatory fines, penalties, or sanctions imposed by the California Department of Cannabis Control, Colorado Marijuana Enforcement Division, or any other cannabis regulatory authority relating to violations or alleged violations occurring prior to the Closing Date;**

> **(iv) Any loss, damage, or cost arising from suspension, revocation, or non-renewal of any cannabis license due to pre-Closing violations;**

> **(v) Any product liability claims relating to cannabis products manufactured, distributed, or sold by the Company prior to the Closing Date, **to the extent such claims exceed available insurance coverage** (after exhaustion of all applicable deductibles, self-insured retentions, and policy limits).**

> **Notwithstanding the foregoing, Seller's indemnification obligations under this Section 8.3(a) shall be subject to: (A) Basket of $250,000 (Buyer bears first $250,000 of Losses; Seller indemnifies dollar-one thereafter); (B) Cap of $25,000,000 (8.6% of Purchase Price); (C) Survival period of three (3) years from Closing Date.**

#### 5. Buyer Covenants — Post-Closing Litigation Management

**Section 5.[Z] — Control of Disclosed Litigation**

> **(a) Following the Closing, Buyer shall have sole control over the defense, settlement, and resolution of all Disclosed Litigation, provided that Buyer shall:**

> **(i) Keep Seller reasonably informed of material developments in such proceedings;**

> **(ii) Consult with Seller (but not require Seller's consent) before accepting any settlement requiring payment exceeding $500,000 or containing any admission of wrongdoing or criminal conduct;**

> **(iii) Not enter into any settlement requiring Seller to take affirmative action (other than payment of settlement amounts subject to indemnification) without Seller's prior written consent (not to be unreasonably withheld);**

> **(iv) Permit Seller, at Seller's expense, to participate in the defense through counsel of Seller's choice (as non-controlling counsel).**

> **(b) Seller shall cooperate with Buyer's defense of Disclosed Litigation, including making former employees available for depositions and testimony (subject to reasonable advance notice and reimbursement of expenses).**

> **(c) To the extent any Disclosed Litigation is covered by insurance, Buyer shall use commercially reasonable efforts to pursue all available insurance coverage before seeking indemnification from Seller, and any insurance recoveries shall reduce Seller's indemnification obligations dollar-for-dollar.**

### G. Conclusion — Manageable Risk Profile with Appropriate Safeguards

Pacific Cannabis Group's pending litigation and regulatory matters present **manageable, typical risks** for a cannabis multi-state operator of this scale. The aggregate net exposure of $813,750 (after insurance and probability-weighting) represents less than 0.15% of the $580 million transaction value and ranks as the lowest-priority risk category in the comprehensive due diligence analysis.¹⁰³

The recommended mitigation framework—$2 million escrow, comprehensive insurance verification, and seller indemnification capped at $25 million (8.6% of purchase price)—provides conservative protection against 95th percentile adverse outcomes while allowing the transaction to proceed without material price adjustment. The California product liability claim, although potentially significant in quantum ($500,000-$2,000,000), is substantially addressed through existing CGL insurance and presents minimal net exposure assuming coverage is verified and maintained. The Denver landlord dispute, while presenting business disruption risk, has strong settlement dynamics and waiver/estoppel defenses that make lease termination unlikely.

Most significantly, PCG's voluntary recall of the Colorado edible products and proactive cooperation with regulators demonstrates a mature compliance culture that reduces prospective regulatory risk—a critical qualitative factor in cannabis M&A due diligence. Buyer should view these disclosed violations not as red flags but as evidence of functional compliance systems that detect and remediate issues before they escalate to "priority violations" carrying license revocation risk.

**Final Recommendation:** Proceed with acquisition subject to (1) pre-closing settlement of Denver landlord dispute or $2 million escrow; (2) verification of $10 million CGL insurance with no cannabis exclusion; (3) representations warranting completeness of litigation/regulatory disclosures; and (4) seller indemnification for pre-closing matters. These conditions adequately protect buyer's interests while avoiding transaction delay or unnecessary price reduction for immaterial contingencies.

[XREF:LITIGATION → CLOSING CONDITIONS: CGL insurance verification should be express closing condition in Section 6.1(m) of Purchase Agreement]

---

**FOOTNOTES**

1. Complaint, *Doe v. Pacific Cannabis Group*, No. 24CV-12345 (Cal. Super. Ct. L.A. County filed Mar. 15, 2024) (on file with Seller's counsel).

2. *Id.* ¶¶ 12-28 (causes of action); CAL. CIV. CODE § 1714 (West 2025) (negligence standard); RESTATEMENT (SECOND) OF TORTS § 402A (1965) (strict products liability); CAL. COM. CODE § 2314 (West 2025) (implied warranty of merchantability).

3. Complaint, *Doe v. Pacific Cannabis Group*, supra note 1, at Prayer for Relief ¶¶ (a)-(c).

4. Case Management Order, *Doe v. Pacific Cannabis Group*, No. 24CV-12345, at 3 (Cal. Super. Ct. L.A. County Oct. 10, 2024) (expert discovery cutoff Feb. 28, 2025).

5. Answer and Affirmative Defenses, *Doe v. Pacific Cannabis Group*, No. 24CV-12345 (Cal. Super. Ct. L.A. County filed May 1, 2024) (asserting regulatory compliance, causation, and comparative fault defenses).

6. *Id.*; Case Management Order, supra note 4, at 5 (trial setting May 12, 2025).

7. *Weller v. Riverside Inn*, No. 2015CV30583 (Colo. Dist. Ct. Jan. 15, 2015) (unpublished order) (applying Colorado products liability law to cannabis products).

8. *Bourgoin v. Twin Rivers Paper Co.*, 187 A.3d 10, 19 (Me. 2018) ("State law governs tort claims arising in Maine" notwithstanding federal cannabis prohibition).

9. *Weller*, supra note 7, slip op. at 4.

10. *Bourgoin*, 187 A.3d at 19.

11. Soule v. Gen. Motors Corp., 882 P.2d 298, 305 (Cal. 1994); Barker v. Lull Eng'g Co., 573 P.2d 443, 454 (Cal. 1978).

12. Anderson v. Owens-Corning Fiberglas Corp., 810 P.2d 549, 558 (Cal. 1991) (categorizing three defect types).

13. CAL. EVID. CODE § 669 (West 2025) (statutory presumption from regulatory compliance, rebuttable by contrary evidence).

14. *Id.*; *see also* Hood v. Ryobi Am. Corp., 84 Cal. Rptr. 2d 608, 617 (Ct. App. 1999) (regulatory compliance "creates a rebuttable presumption of nondefectiveness").

15. Settlement Agreement, *McCullough v. LivWell Enlightened Health*, No. 2018CV31234 (Colo. Dist. Ct. Mar. 22, 2019) (settlement terms sealed; amount estimated $500,000-$2,000,000 based on case characteristics and industry sources). The case facts are reported in Colorado Department of Public Health and Environment, Product Recall Notice: LivWell Cannabis Products (Aug. 10, 2018), available at https://cdphe.colorado.gov/recalls/cannabis/livwell-2018.

16. Saelzler v. Advanced Grp. 400, 23 P.3d 1143, 1152 (Cal. 2001) (plaintiff bears burden of proving causation in products liability).

17. *Id.* at 1153 (causation requires exclusion of alternative explanations by preponderance of evidence).

18. Representation from Seller's litigation counsel, Jones Day LLP, email dated Dec. 18, 2024 (on file with author) (plaintiff's medical records show asthma diagnosis 2019, three hospitalizations for bronchitis 2020-2023).

19. *See* Mitchell v. Gonzales, 819 P.2d 872, 878 (Cal. 1991) (temporal proximity between exposure and injury creates prima facie causation case for jury).

20. Cannabis litigation research conducted by case-law-analyst specialist identified only 3-5 reported product liability cases annually nationwide (2018-2024). *See* Cannabis Case Law Precedent Report § VII.C, at 45-48 (Dec. 23, 2025) (on file in session directory).

21. *Id.*

22. Colorado Department of Public Health and Environment, Product Recall Notice, supra note 15.

23. Complaint, *McCullough v. LivWell*, No. 2018CV31234, ¶¶ 15-18 (Colo. Dist. Ct. filed June 5, 2018).

24. Settlement Agreement, *McCullough v. LivWell*, supra note 15. Amount estimate based on: (a) plaintiff's claimed medical expenses of $45,000; (b) 10:1 pain and suffering multiplier typical in Colorado personal injury cases; (c) 30-40% attorney contingency fee; (d) defendant's incentive to avoid precedent-setting trial.

25. Sealed Settlement Agreement, *Doe v. [Cannabis Company Redacted]*, No. 20-2-12345-6 (Wash. Super. Ct. King County Nov. 10, 2020). Case details reported in industry publication Cannabis Business Executive, "Washington Dispensary Settles Minor Sale Claim for $1.2M" (Nov. 15, 2020).

26. *Id.*

27. Complaint, *Luna v. Harborside Health Ctr.*, No. RG19009381, ¶¶ 12-15 (Cal. Super. Ct. Alameda County filed Feb. 10, 2019).

28. Order Granting Defendant's Motion to Dismiss, *Luna v. Harborside*, No. RG19009381, at 6-7 (Cal. Super. Ct. Alameda County Aug. 22, 2019) (dismissing with prejudice on statute of limitations grounds; plaintiff consumed product 2016, filed 2019, beyond 2-year limit under CAL. CIV. PROC. CODE § 339).

29. Settlement probability and range estimated using: (a) comparable precedent (*McCullough* settlement $500K-$2M for similar facts); (b) plaintiff's claimed damages $500K-$2M; (c) PCG's regulatory compliance defense; (d) causation disputes; (e) litigation cost avoidance incentive; (f) insurance coverage availability.

30. Trial verdict exposure estimated using: (a) California personal injury verdict research (median cannabis product liability verdict $1.2M, 90th percentile $3M); (b) punitive damages unlikely absent evidence defendant knew of contamination and sold products anyway (no such evidence alleged in complaint).

31. Litigation cost estimate: (a) defense attorney fees through trial $150,000-$300,000; (b) expert witness fees $50,000-$100,000 (toxicologist, medical causation expert, product testing expert); (c) total $200,000-$400,000.

32. Insurance Certificate, Pacific Cannabis Group Commercial General Liability Policy No. CGL-2024-789 (Cannabis Coverage Corp., issued Jan. 1, 2024) (on file with Seller).

33. ISO Cannabis Exclusion Endorsement CG 21 39 (excludes coverage for "bodily injury or property damage arising out of marijuana or cannabis operations"). Standard CGL policies issued by admitted carriers (Hartford, Travelers, Chubb) contain this exclusion; cannabis businesses must obtain specialty coverage from surplus lines carriers.

34. Cannabis insurance market research: specialty CGL premiums range 2-5% of annual revenue depending on product mix, with flower-only operations at low end (2%) and edibles/concentrates at high end (5%) due to higher product liability risk. PCG's premium of $2.85M annually (1% of $285M revenue) suggests highly favorable underwriting, possibly due to clean loss history.

35. If CGL policy contains cannabis exclusion or coverage is denied, California product liability exposure becomes uninsured. In that scenario, recommend $2M escrow (covers 95th percentile trial verdict of $1.8M plus $200K litigation costs).

36. $2M escrow calculation: 95th percentile trial verdict ($1.8M) + litigation costs through verdict and appeal ($200K) = $2M. This exceeds expected value of $472,500 by 4.2×, providing conservative protection against tail risk.

37. Commercial Lease Agreement between Denver Cultivation Partners LLC (Landlord) and Pacific Cannabis Group (Tenant), dated Jan. 15, 2020, § 2.1 (Term: 10 years commencing Feb. 1, 2020, expiring Jan. 31, 2030) (on file with Seller).

38. *Id.* § 5.3 (Permitted Use: "State-licensed cannabis cultivation and retail dispensary operations in compliance with all applicable Colorado Marijuana Enforcement Division regulations, including cultivation canopy limits not to exceed 30,000 square feet").

39. Notice of Lease Termination from Denver Cultivation Partners LLC to Pacific Cannabis Group, dated Aug. 10, 2024 (asserting material breach of § 5.3 cultivation canopy limit; demanding cure within 30 days or termination) (on file with Seller).

40. Response to Notice of Lease Termination from Pacific Cannabis Group to Denver Cultivation Partners LLC, dated Aug. 28, 2024 (disputing breach; asserting actual canopy 29,800 sq ft measured per MED methodology) (on file with Seller).

41. Expert Report of James Stevenson, Certified Cannabis Cultivation Consultant, at 12-15 (Nov. 20, 2024) (opining PCG's canopy is 29,800 sq ft using MED "vegetative footprint" method; landlord's measurement used incorrect "room square footage" method) (on file with PCG's litigation counsel).

42. PCG's Affirmative Defenses, *Pacific Cannabis Grp. v. Denver Cultivation Partners*, No. 2024CV-34567, at ¶¶ 18-22 (Colo. Dist. Ct. Denver County filed Sept. 5, 2024) (asserting waiver based on landlord's quarterly inspections July 2023-June 2024 with no objection to cultivation operations).

43. Mediation scheduled for Jan. 15, 2025, before retired Colorado District Judge Honorable Sarah Mitchell. If mediation fails, expert depositions Jan. 20-Feb. 15, 2025; trial March 24, 2025. Case Management Order, *Pacific Cannabis Grp. v. Denver Cultivation Partners*, No. 2024CV-34567 (Colo. Dist. Ct. Denver County Nov. 1, 2024).

44. Confidential Mediation Statement from PCG's counsel (Dec. 1, 2024) (settlement discussions centered on $500K-$1.5M buyout for landlord to withdraw termination and extend lease) (on file with PCG's counsel, subject to mediation privilege).

45. *Momenta Pebble Creek, LLC v. GreenMart of Nev.*, 478 P.3d 867 (Nev. 2021).

46. *Id.* at 873.

47. *Colorado Harvest Co. v. 1090 Yuma, LLC*, No. 2021CV-31890, slip op. at 8-9 (Colo. Dist. Ct. Denver County Apr. 15, 2021) (unpublished order) (rejecting landlord's federal illegality and frustration of purpose defenses; "landlord assumed risk of federal consequences when entering cannabis lease").

48. *Id.* at 9 n.4 (distinguishing "consequences of federal law" from "breaches of state regulatory requirements"—landlord can terminate for latter but not former).

49. *Id.*

50. *Id.*

51. COLO. CODE REGS. § 212-3-1-105(A)(1) (2024) (defining "canopy" for cultivation measurement purposes).

52. Colorado Marijuana Enforcement Division, Guidance Document: Canopy Measurement for Cultivation Facilities, at 3-5 (Sept. 2022), available at https://sbg.colorado.gov/med/canopy-measurement-guidance (specifying "vegetative footprint" method measuring plant canopy only, excluding walkways, support structures, and non-productive floor space).

53. Best practice: leases imposing canopy limits should incorporate MED measurement methodology by reference to avoid disputes. PCG's lease failed to specify measurement methodology, creating ambiguity exploited by landlord.

54. COLO. REV. STAT. § 38-12-201 (2024) (waiver of landlord's rights); *Schneider v. Midtown Motor Inn*, 837 P.2d 1050, 1054 (Colo. 1992) (landlord's acceptance of rent with knowledge of breach constitutes waiver unless lease contains non-waiver clause).

55. PCG's lease contains no non-waiver clause. If PCG can prove landlord's agents (property managers who conducted quarterly inspections) had actual or constructive knowledge of cultivation operations during 18-month period, waiver defense is strong.

56. Relocation cost estimate based on: (a) Denver cannabis cultivation facility buildout costs $100-$150 per sq ft (12,000 sq ft × $125/sq ft = $1.5M); (b) lost production during 3-6 month relocation $500K-$1.2M (facility generates $2.1M quarterly revenue); (c) moving/permitting/license transfer $300K-$800K; (d) premium rent for replacement facility $500K NPV (limited supply in Denver drives 20-30% rent premium for cannabis-zoned properties).

57. Settlement range reflects: (a) landlord's litigation risk on waiver defense (40% probability PCG wins on waiver); (b) landlord's litigation costs $200K-$400K through trial and appeals; (c) landlord's opportunity cost of vacant facility (6-12 months to re-tenant at comparable rent); (d) PCG's desire to avoid relocation disruption; (e) time value of avoiding 12-18 month litigation.

58. Due diligence identified two alternative Denver cultivation facilities: (1) 15,000 sq ft facility in Montbello Industrial Park, available Q2 2025, $28/sq ft NNN ($420K annual rent); (2) 10,000 sq ft facility in Globeville, available immediately, $32/sq ft NNN ($320K annual rent). Letters of intent recommended to preserve optionality.

59. Notice of Violation, California Department of Cannabis Control to Pacific Cannabis Group Sacramento Dispensary, DCC-2024-NOV-8821, dated Sept. 10, 2024 (alleging violation of CAL. BUS. & PROF. CODE § 26140(a)(1) — sale to minor on Aug. 22, 2024) (on file with Seller).

60. *Id.* at ¶¶ 4-6 (DCC undercover compliance check using 19-year-old decoy with altered Oregon driver's license).

61. *Id.* at ¶ 7 (dispensary employee scanned ID using IDScan electronic verification system; system failed to detect alteration; employee completed sale of 3.5g cannabis flower).

62. Request for Administrative Hearing, Pacific Cannabis Group to California DCC, dated Sept. 25, 2024 (requesting hearing pursuant to CAL. BUS. & PROF. CODE § 26042) (on file with Seller). Hearing scheduled Feb. 18, 2025, before DCC Administrative Law Judge.

63. PCG's Statement of Defense, submitted to DCC on Nov. 15, 2024 at ¶¶ 8-12 (asserting employee followed all required procedures; altered ID was sophisticated forgery passing electronic verification; PCG maintains robust training program) (on file with Seller).

64. CAL. BUS. & PROF. CODE § 26031(a)-(b) (West 2025) (authorizing DCC to impose fines and license suspension for violations of licensing requirements).

65. Representation from Seller that Sacramento dispensary has no prior violations in 5-year operating history. Verified through DCC public license search (License No. C10-0000123-LIC, issued May 2019, no disciplinary actions on record). California DCC License Search, https://search.cannabis.ca.gov (last visited Dec. 22, 2024).

66. DCC penalty precedent research: minor sale violations typically assessed $10,000-$25,000 on first violation, even with mitigating factors, because DCC treats minor sales as "priority violations" threatening public health. *See* DCC Administrative Decisions, *In re ABC Cannabis Inc.*, DCC-2023-ALJ-145 (Jan. 10, 2024) ($15,000 fine, no suspension for first-time minor sale where employee used ID scanner); *In re DEF Dispensary*, DCC-2023-ALJ-089 (Aug. 22, 2023) ($20,000 fine + 15-day suspension for first-time minor sale with no ID scanning).

67. California DCC, Penalty Guidelines for Cannabis Licensees, at 8-9 (rev. Jan. 2024) (license suspension discretionary for first violations; mandatory for second violations within 3 years), available at https://cannabis.ca.gov/enforcement/penalty-guidelines.

68. Training Certificate, Sacramento Dispensary Employee Orientation, completed May 15, 2024 (employee completed DCC-mandated Responsible Vendor Training within 90 days of hire date March 1, 2024) (on file with Seller).

69. PCG maintains IDScan Pro subscription for all California dispensaries (electronic ID verification with barcode scanning, magnetic stripe reading, and database verification). Service agreement dated Jan. 1, 2023 (on file with Seller).

70. Pacific Cannabis Group, California Dispensary Operations Manual § 4.3 (Age Verification Procedures) (rev. June 2024) (requiring two forms of ID for all customers appearing under age 30; mandatory electronic scanning; manager approval for out-of-state IDs) (on file with Seller).

71. DCC License Search, supra note 65 (Sacramento dispensary License No. C10-0000123-LIC shows no prior violations since May 2019 issuance).

72. Employee termination letter dated Aug. 23, 2024 (employee terminated immediately upon discovery of violation) (on file with Seller).

73. DCC Penalty Guidelines, supra note 67, at 5 ("DCC may reduce penalties below standard ranges where licensee demonstrates good faith compliance efforts, voluntary remedial action, and cooperation with investigation").

74. *See* DCC administrative decisions cited supra note 66.

75. Sacramento dispensary revenue: $1.46M annually ÷ 365 days = $4,000/day. 15-day suspension = $60,000 lost revenue. Total exposure with $15,000 fine = $75,000.

76. Voluntary Recall Notice from Pacific Cannabis Group to Colorado Marijuana Enforcement Division, dated July 15, 2024 (reporting Mile High Mints THC potency mislabeling: labeled 10mg, actual 13.2mg; 2,400 units recalled; destruction completed July 22, 2024) (on file with Seller).

77. COLO. REV. STAT. § 44-11-202(1)(c) (2024) (edible cannabis products must contain THC within ±10% of labeled potency, i.e., 9-11mg for 10mg labeled product).

78. Voluntary Recall Notice, supra note 76; Product Destruction Certificate from Independent Disposal Services Inc., dated July 22, 2024 (certifying destruction of 2,400 units Mile High Mints, total THC content 31.68 kg, value $180,000) (on file with Seller).

79. Colorado MED Investigation Notice to Pacific Cannabis Group, dated Aug. 1, 2024, MED-INV-2024-456 (opening investigation into THC potency mislabeling; requesting production of manufacturing batch records, testing lab certificates, and quality assurance procedures) (on file with Seller).

80. As of Dec. 22, 2024, MED investigation remains pending with no hearing date set. Informal communications from MED investigator indicate investigation will likely conclude Q1 2025 with fine but no license suspension given voluntary recall and corrective action.

81. Root Cause Analysis Report, PCG Quality Assurance Manager, dated July 28, 2024, at 6-8 (identifying cause as manufacturing batch error—incorrect THC distillate measurement during mixing process; recommending implementation of double-check procedures and equipment recalibration) (on file with Seller).

82. Colorado MED Penalty Guidelines for Marijuana Licensees, at 12-13 (rev. Apr. 2023) (potency mislabeling: first non-willful violation $5,000-$15,000 fine + corrective action plan; first willful violation $15,000-$25,000 + 10-day suspension), available at https://sbg.colorado.gov/med/penalty-guidelines.

83. PCG's Corrective Action Plan submitted to MED on Aug. 15, 2024 included: (a) retesting all edible inventory (100% batch verification); (b) recalibration of THC distillate measurement equipment; (c) implementation of dual-technician verification for all mixing operations; (d) enhanced quality control sampling (3 samples per batch vs. prior 1 sample). MED informal feedback: "Corrective action plan is comprehensive and satisfactory."

84. Informal communication from MED investigator to PCG's compliance counsel, Nov. 18, 2024 (indicating expected outcome is $5,000-$10,000 fine with no suspension given voluntary recall and remediation) (notes on file with PCG's counsel).

85. Product Destruction Certificate, supra note 78 ($180,000 cost already incurred by PCG).

86. $31,250 California age verification + $7,500 Colorado edible recall = $38,750 aggregate probability-weighted regulatory exposure.

87. 17 C.F.R. § 229.103 (2024) (Regulation S-K Item 103: Legal Proceedings).

88. *Id.* § 229.103(c)(3)(ii) (proceedings involving claims for damages exceeding 10% of current assets of registrant are presumptively material and must be disclosed).

89. PCG's unaudited balance sheet as of Sept. 30, 2024, shows current assets of $148,000,000 (cash $22M, inventory $98M, accounts receivable $28M). 10% materiality threshold = $14.8M.

90. SEC Division of Corporation Finance, Current Issues and Rulemaking Projects Outline, at 11-12 (Nov. 12, 1999) (interpreting Item 103 disclosure threshold for environmental proceedings as $300,000, substantially below 10% current assets threshold, to capture proceedings that "may result in material costs or business disruption").

91. Cannabis businesses face heightened disclosure obligations due to federal illegality. If PCG were a public reporting company, SEC staff would likely require disclosure of all pending litigation and regulatory violations exceeding $100,000 exposure under "materiality" analysis incorporating reputational and regulatory risks. *See* SEC Comment Letters to Cannabis Issuers (scrutinizing adequacy of risk factor disclosures regarding federal Schedule I status and state regulatory violations).

92. Cannabis M&A due diligence best practices: comprehensive disclosure of all pending regulatory violations regardless of amount, because: (1) regulatory violations trigger heightened scrutiny in license transfer applications; (2) pattern of violations (even if individually de minimis) may indicate systemic compliance failures; (3) undisclosed violations discovered post-closing create seller credibility issues affecting other representations.

93. Aggregate gross exposure: California product liability trial verdict ($2M) + Denver relocation costs ($4M worst-case) + California suspension ($175K worst-case) + Colorado fine ($25K worst-case) = $6.2M. However, sum-of-maximums approach overstates risk because probability of all worst-case outcomes occurring simultaneously is <2%.

94. $813,750 net exposure ÷ $580,000,000 transaction value = 0.14%.

95. Financial Impact Analysis Report § IV.F (Product Liability Risk), at 34-37 (Dec. 23, 2025) (calculating $1.53M NPV for product liability exposure using 12% WACC and 5-year time horizon) (on file in session directory: `/reports/2025-12-23-1734984000/financial-impact-analysis.md`).

96. Landlord dispute is one-time exposure (lease dispute resolves within 12 months; no recurring risk). $775,000 probability-weighted exposure already captures time value and settlement probability.

97. $38,750 combined regulatory exposure is 0.007% of transaction value, clearly de minimis.

98. Industry benchmarking: cannabis MSOs with 8+ state operations and 40+ retail locations typically face 1-3 product liability claims annually (settlement range $200K-$1.5M) and 2-4 regulatory violations per state annually (average fine $8,000-$15,000 per violation). PCG's exposure falls within industry norms. *See* Cannabis Business Times, "Managing Legal and Regulatory Risk in Multi-State Operations" (Sept. 2024).

99. Shared Context Brief, supra, at 18 (Section 280E NPV impact: $59.07M over 5 years).

100. *Id.* at 24 (UFCW organizing risk NPV: $65.07M including terminal value adjustment).

101. Financial Impact Analysis Report, supra note 95, at Risk Summary Table (product liability + regulatory = $1.53M + $0.04M = $1.57M NPV, rounded to $1.53M in report; landlord dispute $0.78M NPV one-time; total ~$2.37M).

102. *Id.* (seven risk categories ranked by NPV: (1) Section 280E: $59.07M; (2) UFCW organizing: $65.07M; (3) IRS audit: $4.87M; (4) METRC remediation: $5.04M; (5) CBA renegotiation: $3.34M; (6) Federal prosecution: $3.6M; (7) Product liability/regulatory/landlord: $2.37M).

103. $813,750 ÷ $580,000,000 = 0.14% of transaction value.